- SILO issued US Patent by USPTO titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females”
- Claims allowed by patent protect use of SPC-15 for treating stress-induced affective disorders, including anxiety and PTSD
- Other therapeutics in company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, SPC-14 to treat Alzheimer’s disease
- Therapeutics developed by SILO may qualify for FDA’s streamlined 505(b)(2) regulatory drug approval pathway
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued US Patent 11,491,120 by the US Patent and Trademark Office (“USPTO”) (https://ibn.fm/rMLOR). The patent, titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females”, enables SILO to expand its intellectual property and technology rights for treating rare stress-related medical conditions.
SPC-15 is a targeted prophylactic ketamine formulation used in a novel protocol to treat and prevent stress-induced affective disorders, including PTSD.
“After a comprehensive review by USPTO, we are pleased with the scope of the granted claims offering further protection for our novel SPC-15 technology and its market potential for anxiety, PTSD, and related disorders,” said SILO Chief Executive Officer Eric Weisblum.
SILO collaborates with first-in-class research partners at leading universities to advance research in the medical and psychedelic sectors. The company holds an option to license certain assets currently under development by Columbia University through a commercial evaluation license agreement between both parties. Other drugs in the company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, and SPC-14 as a treatment for Alzheimer’s disease.
Several therapeutics developed by the company may qualify for the FDA’s streamlined 505(b)(2) regulatory drug approval pathway. Drugs that qualify under the 505(b)(2) pathway may be exempted from conducting repeat studies previously performed on tested drugs, enabling the company to reduce expenses and speed up the time to market (https://ibn.fm/BiKBw). Other benefits include lower treatment risk due to previous drug approval and the potential to qualify for 3-7 years of market exclusivity.
Silo Pharma Inc. merges traditional therapeutics with psychedelic research to develop innovative therapeutics for underserved markets, including PTSD, fibromyalgia, Alzheimer’s disease, Parkinson’s disease, rheumatoid arthritis, and other rare neurological conditions. The company collaborates with top universities and research institutions to develop therapeutics that can improve patient outcomes and potentially transform the healthcare industry.
For more information, visit the company’s website at www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment